Cargando…

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes

The purpose of this study is to evaluate the predictive performance of magnetic resonance imaging (MRI) markers in breast cancer patients by subtype. Sixty-four patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy were enrolled in this study. Each patient received a dynam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lo, Wei-Ching, Li, Wen, Jones, Ella F., Newitt, David C., Kornak, John, Wilmes, Lisa J., Esserman, Laura J., Hylton, Nola M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757528/ https://www.ncbi.nlm.nih.gov/pubmed/26886725 http://dx.doi.org/10.1371/journal.pone.0142047

Ejemplares similares

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL
por: Li, Wen, et al.
Publicado: (2016)

Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
por: Onishi, Natsuko, et al.
Publicado: (2020)

Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer
por: Li, Wen, et al.
Publicado: (2020)

MRI Enhancement in Stromal Tissue Surrounding Breast Tumors: Association with Recurrence Free Survival following Neoadjuvant Chemotherapy
por: Jones, Ella F., et al.
Publicado: (2013)

Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
por: Wilmes, Lisa J., et al.
Publicado: (2016)

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
por: Olshen, Adam, et al.
Publicado: (2017)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer
por: Le, Nu N., et al.
Publicado: (2022)

Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration
por: Jahani, Nariman, et al.
Publicado: (2019)

Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy
por: Nguyen, Alex Anh-Tu, et al.
Publicado: (2020)

Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
por: Chitalia, Rhea, et al.
Publicado: (2023)

Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response
por: Nguyen, Alex Anh-Tu, et al.
Publicado: (2022)

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Mukhtar, Rita A., et al.
Publicado: (2013)

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis
por: Huang, Shih-ying, et al.
Publicado: (2018)

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Evaluation of primary breast cancers using dedicated breast PET and whole-body PET
por: Hathi, Deep K., et al.
Publicado: (2020)

Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial
por: Thakran, Snekha, et al.
Publicado: (2022)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

Agreement of Mammographic Measures of Volumetric Breast Density to MRI
por: Wang, Jeff, et al.
Publicado: (2013)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
por: Li, Wen, et al.
Publicado: (2020)

Multi-Site Clinical Evaluation of DW-MRI as a Treatment Response Metric for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Galbán, Craig J., et al.
Publicado: (2015)

MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis
por: Janssen, L. M., et al.
Publicado: (2022)

Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study
por: Malyarenko, Dariya I., et al.
Publicado: (2020)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and (18)F-FDG PET/CT in breast cancer subtypes
por: Schmitz, Alexander M. Th., et al.
Publicado: (2017)

Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1
por: Chitalia, Rhea, et al.
Publicado: (2022)

Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI
por: Liu, Yongguang, et al.
Publicado: (2022)

Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype
por: Ko, Eun Sook, et al.
Publicado: (2015)

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
por: Thompson, Kevin J, et al.
Publicado: (2022)

Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial
por: Partridge, Savannah C., et al.
Publicado: (2022)

Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes
por: Adham, Sirin A., et al.
Publicado: (2022)

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
por: Lips, E. H., et al.
Publicado: (2013)

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol
por: Jones, Ella F., et al.
Publicado: (2019)

Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes
por: de Ronde, Jorma J., et al.
Publicado: (2014)

Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT
por: An, Yeong Yi, et al.
Publicado: (2015)

Correlation of post-neoadjuvant chemotherapy response on MRI with final histology in breast cancer patients
por: Mahatma, Anjum, et al.
Publicado: (2015)

Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy
por: Busch, David R., et al.
Publicado: (2012)

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
por: Yu, Katharine, et al.
Publicado: (2023)

Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome
por: Lim, Siew Kuan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h7du3entj3jei9a47n4vcuvo7b